# GLP-1 maintenance: what happens after reaching a goal?

Withdrawal trials show that weight regain is common after treatment stops. They inform maintenance planning but do not predict one person’s future.

Canonical: https://velri.co/blog/glp1-lifetime-sentence-maintenance-myth-goal-weight-optimizer
Publisher: Velri (https://velri.co/about)
Published: 2026-07-11
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Reaching a weight goal does not automatically end the need for treatment. Studies of semaglutide and tirzepatide show that weight regain is common after withdrawal. Those results support planning for maintenance before deciding whether to stop. [1][2]

## What happened after semaglutide stopped?

In an extension of the STEP 1 trial, participants were followed for a year after semaglutide and the study's lifestyle intervention ended. On average, the semaglutide group regained about two-thirds of its previous weight loss. Some cardiometabolic improvements also moved back toward baseline. [1]

This was an exploratory follow-up of a subset of trial participants. Because both medication and the structured lifestyle intervention stopped, the study describes that combined withdrawal setting rather than every possible maintenance approach. [1]

## What did continued tirzepatide treatment show?

SURMOUNT-4 randomized people who had completed an initial tirzepatide period to either continue treatment or switch to placebo. Continuing treatment maintained and added to the initial weight reduction; switching to placebo led to substantial regain on average. [2]

This was a comparison of continued treatment with withdrawal, not a test of lower-dose or intermittent maintenance. [2]

## How is the long-term decision made?

NIDDK describes the duration of weight-management medication use as depending on benefit and serious side effects. Continued treatment may be appropriate when it supports health and remains tolerable. Cost, other health conditions and individual preferences also belong in medication decisions. [3]

A maintenance conversation can therefore consider several questions: whether the health benefit persists, whether side effects or expense have changed, and how weight and related health measures would be followed if treatment changed. [3]

Maintenance may require ongoing treatment. The plan can be reassessed over time, with a clear understanding of what stopping could mean. [1][2][3]

## Sources
[1] Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. (2022). https://pubmed.ncbi.nlm.nih.gov/35441470/
[2] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. (2024). https://pubmed.ncbi.nlm.nih.gov/38078870/
[3] Prescription Medications to Treat Overweight & Obesity - NIDDK (2025). https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support